XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.50
+0.21 (+0.45%)
At close: 4:00PM EDT

46.50 0.00 (0.00%)
After hours: 4:16PM EDT

Stock chart is not supported by your current browser
Previous Close46.29
Open46.21
Bid32.53 x 800
Ask47.50 x 1200
Day's Range44.52 - 46.72
52 Week Range29.57 - 50.00
Volume243,377
Avg. Volume453,333
Market Cap2.129B
Beta1.67
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.00
Trade prices are not sourced from all markets
  • ACCESSWIRE9 hours ago

    Free Pre-Market Technical Recap on Genesis Healthcare and Three Additional Healthcare Stocks

    On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).

  • Benzinga5 days ago

    Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target

    Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note.

  • Business Wire6 days ago

    Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD). “We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.

  • Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
    Zacks7 days ago

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

  • Celgene, Acceleron Report Positive Data on Thalassemia Drug
    Zacks8 days ago

    Celgene, Acceleron Report Positive Data on Thalassemia Drug

    Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.

  • Barrons.com8 days ago

    Upbeat Celgene Data Not Enough to Lift Biotech Sector

    Shares of Celgene (CELG) and Acceleron Pharma (XLRN) are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. Acceleron is up 2.3% to $48.50, while Celgene is climbing 0.9% to $84.60.

  • Benzinga8 days ago

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

  • The Wall Street Journal9 days ago

    [$$] Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results

    Inc. reported positive results from a trial of their drug Luspatercept, a drug to treat chronic anemia, beta-thalassemia and myelofibrosis. The results announced Monday, the companies said, reflect testing on beta-thalassemia patients who are dependent on blood transfusions. Patients showed at least a one-third reduction in dependence on transfusions, the companies said.

  • MarketWatch9 days ago

    Celgene, Acceleron shares rise on blood-disorder drug study

    MARKET PULSE Celgene Corp. (celg) and Acceleron Pharma Inc. (xlrn) shares pushed higher in the extended session Monday after the biotech companies said a clinical trial showed their jointly developed drug was effective in treating a certain type of inherited blood disorder.

  • Business Wire9 days ago

    Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 percent reduction from baseline in red blood cell (RBC) transfusion burden with a reduction of at least 2 units during the protocol-defined period of 12 consecutive weeks, from week 13 to week 24, compared to placebo. BELIEVE evaluated the efficacy and safety of luspatercept plus best supportive care versus placebo plus best supportive care in adults with transfusion-dependent beta-thalassemia.

  • Why Analysts are Mostly Positive On Acceleron Pharma
    Market Realist9 days ago

    Why Analysts are Mostly Positive On Acceleron Pharma

    After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.

  • Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
    Business Wire13 days ago

    Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablynx NV. “Robert has built an impressive career, holding a variety of leadership positions across clinical development, regulatory, and medical affairs functions,” said Habib Dable, Chief Executive Officer of Acceleron.

  • ACCESSWIRE16 days ago

    Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Acceleron Pharma and Vertex Pharmaceuticals both saw big gains on Friday on separate positive catalysts last week. Acceleron and Celgene reported strong results ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool18 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these high-flying biotech stocks keep up their momentum?

  • Celgene Investors Breathe a Sigh of Relief After Acceleron's Success
    Motley Fool18 days ago

    Celgene Investors Breathe a Sigh of Relief After Acceleron's Success

    Shareholders got much-needed good news this week from one of Celgene's key collaboration partners.

  • Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment
    Investor's Business Daily19 days ago

    Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment

    Acceleron Pharma shares rocketed early Friday after it and Celgene reported strong results for a partnered anemia treatment called luspatercept.

  • Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals
    Market Realist19 days ago

    Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals

    Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal. Acceleron said that the drug reported a significant reduction in the need for blood transfusions in patients with MDS (myelodysplastic syndrome). CELG and XLRN stocks rose ~4% and 42%, respectively.

  • Celgene's Luspatercept Meets Primary Endpoint in the Study
    Zacks19 days ago

    Celgene's Luspatercept Meets Primary Endpoint in the Study

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.

  • A Huge Win Sends Acceleron Pharma Shares Soaring 42%
    Motley Fool19 days ago

    A Huge Win Sends Acceleron Pharma Shares Soaring 42%

    Data for the company's most advanced clinical-stage drug sets the stage for a filing for FDA approval.

  • Benzinga19 days ago

    Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying

    Acceleron Pharma Inc (NASDAQ: XLRN ), a clinical-stage biopharmaceutical focused on the treatment of serious and rare diseases, saw its stock soar after reporting encouraging Phase 3 data . But investors ...

  • Benzinga19 days ago

    Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...

  • Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
    Business Wire20 days ago

    Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo. MEDALIST evaluated the efficacy and safety of luspatercept versus placebo in patients with IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) with chronic anemia and refractory to, intolerant of, or ineligible for treatment with an erythropoietin-stimulating agent (ESA), ring sideroblast-positive and require frequent RBC transfusions.

  • Business Wire22 days ago

    Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from the ongoing Phase 2 trial in patients with Charcot-Marie-Tooth (CMT) disease at the Peripheral Nerve Society (PNS) annual meeting held in Baltimore, Maryland, July 22-25, 2018. Part 1 is an open-label, dose-escalation study, with ACE-083 administered by injection into the TA muscle once every 3 weeks in up to 18 patients to evaluate safety and increases in muscle volume over a 3-month treatment period.

  • GlobeNewswire26 days ago

    Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination Maternity, The RMR Group, and Cohen & Steers — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, June 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RCI ...

  • Business Wirelast month

    Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in patients with beta-thalassemia during an oral presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene. “These results reinforce our enthusiasm for luspatercept’s potential as a safe, efficacious therapy for beta-thalassemia patients over the long term,” said Habib Dable, President and Chief Executive Officer of Acceleron.